Jaguar Health Launches Phase 2 Study for Microvillus Inclusion Disease

Jaguar Health, Inc. has initiated a Phase 2 study to evaluate the efficacy of crofelemer, a plant-based prescription drug, for Microvillus Inclusion Disease (MVID) in pediatric patients. Crofelemer has received Orphan-Drug Designation from the FDA and European Medicines Agency. The study, involving double-blind, placebo-controlled trials, marks a significant step for Jaguar's clinical efforts in rare diseases.

Lisa Conte, Jaguar's CEO, emphasized the importance of this milestone. The study is part of a broader initiative encompassing three proof-of-concept trials and two Phase 2 studies targeting rare conditions like MVID and short bowel syndrome with intestinal failure.

MVID, characterized by severe diarrhea and malabsorption, affects a small global population. Currently, there are no approved drug treatments for this condition. Jaguar hopes positive outcomes could lead to U.S. approval and expanded patient access in certain EU countries.